• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Importance Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet
therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …

Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor prevents
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …